3H Health Investment | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/3H Health Investment/Activity

3H Health Investment Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Portfolio company Alebund Pharmaceuticals (renal disease biopharmaceuticals) debuted on the HKEX main board (09637.HK).

Alebund Pharmaceuticals

Alebund Pharmaceuticals 3H Health Investment

prnewswire.comJUN 29, 2026

JUN 29, 2026

Investment

Participated in Angitia Biopharmaceuticals' $130M Series D financing.

Angitia Biopharmaceuticals

Angitia Biopharmaceuticals 3H Health Investment

biospace.comFEB 5, 2026

3hhinvestment.com

fiercebiotech.com

FEB 5, 2026

Exit

Portfolio company Edge Medical Robotics (精锋医疗), in which 3H is the largest institutional shareholder, completed its IPO on the Hong Kong Stock Exchange (2675.HK).

Edge Medical Robotics

Edge Medical Robotics 3H Health Investment

3hhinvestment.comJAN 8, 2026

JAN 8, 2026

Exit

Portfolio company Edge Medical (surgical robotics) completed its HKEX main board IPO (2675.HK); 3H is the largest institutional shareholder.

Edge Medical

Edge Medical 3H Health Investment

3hhinvestment.comJAN 8, 2026

JAN 8, 2026

Investment

Participated in Timberlyne Therapeutics' $180M Series A financing to advance CM313, an anti-CD38 monoclonal antibody.

Timberlyne Therapeutics

Timberlyne Therapeutics Keymed Biosciences 3H Health Investment

prnewswire.comJAN 9, 2025

3hhinvestment.com

JAN 9, 2025

Investment

Participated in Angitia Biopharmaceuticals' $120M Series C financing for musculoskeletal disease therapeutics.

Angitia Biopharmaceuticals

Angitia Biopharmaceuticals 3H Health Investment

globenewswire.comDEC 11, 2024

3hhinvestment.com

DEC 11, 2024

Milestone

Portfolio company Keymed Biosciences received NMPA approval for stapokibart (康悦达®), the first domestically developed IL-4Rα antibody approved in China.

Keymed Biosciences

Keymed Biosciences 3H Health Investment

3hhinvestment.comSEP 12, 2024

SEP 12, 2024

New Fund

Closed an oversubscribed second USD fund exceeding $300M, focused on China healthcare.

USD Fund II

3H Health Investment

startup.aliyun.comNOV 2, 2021

NOV 2, 2021